HealthQuill therapeutics
Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and expand, filling and freeze dryer capacity, according to a company statement.
Drugs Health Pharma

Merck Animal Health to invest $895 million to expand facility in US

HQ Team May 8, 2025: Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and.

Read More
Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations of the US-based company’s peptides for an upfront payment of $493 million.
Drugs Health Medical

Austria’s Cyprumed in $493 million pact with Merck to develop peptides

HQ Team April 17, 2025: Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations.

Read More
GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights to develop and commercialise the US company’s hepatitis B therapy.
Drugs Health Pharma

GSK to pay $1 billion to acquire exclusive rights for J&J hepatitis B therapy

 HQ Team November 1, 2023: GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights.

Read More
AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in oncology, immunology and rare diseases.
Drugs Health Pharma

AstraZeneca inks $245 million deal with Cellectis for rare diseases

HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.

Read More
Drugs Health Medical Pharma

Lab-made lung models facilitate faster drug testing and substitute animal subjects

Scientists in Australia have developed accurate lab models of human lungs that will help in therapeutic testings and do away with the need.

Read More